InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (5 ops.)
Insider track record
Board DirectorDisclosed buys
7
Disclosed sells
5
T+90 hit rate
89%
T+90 mean return
+25.5%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Coleman Mark, Director. Insider active across 1 company, notably Axsome Therapeutics, Inc.. Aggregated, 18 reports have been logged. Breakdown: 7 buys · 5 sells. Total volume traded: €4.4m. Activity tracked since 12 May 2021. The latest transaction was disclosed on 2 June 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
6,000 shares@ US$233.460.013% mcap25.6% of flowCommon StockSEC:0001193125-26-254038:0
6,000 shares@ US$230.300.013% mcap25.2% of flowCommon StockSEC:0001193125-26-254038:1
5,537 shares@ US$223.390.011% mcap22.6% of flowCommon StockSEC:0001193125-26-254038:2
5,193 shares@ US$8.020.7% of flowCommon StockSEC:0001193125-26-045110:0
800 shares@ US$127.201.8% of flowCommon StockSEC:0000950170-25-113874:0
Ideal exit: 5 Jun 2026 (T+270)
287 shares@ US$127.300.7% of flowCommon StockSEC:0000950170-25-113874:1
Ideal exit: 5 Jun 2026 (T+270)
488 shares@ US$127.401.1% of flowCommon StockSEC:0000950170-25-113874:2
Ideal exit: 5 Jun 2026 (T+270)
3,000 shares@ US$107.4916.1% of flowCommon StockSEC:0000950170-25-075539:0
9,127 shares@ US$9.001.7% of flowCommon StockSEC:0000950170-25-002052:0
33,410 shares@ US$5.944.0% of flowCommon StockSEC:0000950170-24-129330:0
5,249 shares@ US$75.20957.7% of flowCommon StockSEC:0000950170-24-066175:0
11,016 shares@ US$3.6727.8% of flowCommon StockSEC:0001209191-23-049648:0
17,501 shares@ US$1.300.5% of flowCommon StockSEC:0001209191-23-000870:0
3,496 shares@ US$1.300.0000% mcap5.3% of flowCommon StockSEC:0001209191-22-019403:0
409 shares@ US$35.070.0001% mcap16.3% of flowCommon StockSEC:0001209191-21-066004:0
Ideal exit: 15 Aug 2022 (T+270)
409 shares@ US$35.0734.5% of flowCommon StockSEC:0001209191-21-066004
Ideal exit: 15 Aug 2022 (T+270)
500 shares@ US$58.1531.0% of flowCommon StockSEC:0001209191-21-032250
Ideal exit: 6 Feb 2022 (T+270)
500 shares@ US$58.150.0003% mcap31.0% of flowCommon StockSEC:0001209191-21-032250:0
Ideal exit: 6 Feb 2022 (T+270)
18 of 18 declarations
About Coleman Mark
Mark Coleman is a Board Member at Axsome Therapeutics, Inc., a biopharmaceutical company. As a board member, he participates in the strategy and management of the company. His expertise in the pharmaceutical sector is an asset for Axsome.
